EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7

Matteo Boretto, Maarten H Geurts, Shashank Gandhi, Ziliang Ma, Nadzeya Staliarova, Martina Celotti, Sangho Lim, Gui-Wei He, Rosemary Millen iD, Else Driehuis, Harry Begthel, Lidwien Smabers und 4 weitere

Proceedings of the National Academy of Sciences · 19.03.2024 · 121 (12)

DOI: 10.1073/pnas.2309902121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 14.03.2024. Verfasst von Matteo Boretto und 15 weiteren Autor:innen. Beteiligte Einrichtung: Organoid group, Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, 3584 CT Utrecht, …. Hauptthemen laut MEDLINE: Neoplasms, F-Box Proteins. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Molecular Biology Organization (EMBO).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FBXW7 is an E3 ubiquitin ligase that targets proteins for proteasome-mediated degradation and is mutated in various cancer types. Here, we use CRISPR base editors to introduce different FBXW7 hotspot mutations in human colon organoids. Functionally, FBXW7 mutation reduces EGF dependency of organoid growth by ~10,000-fold. Combined transcriptomic and proteomic analyses revealed increased EGFR protein stability in FBXW7 mutants. Two distinct phosphodegron motifs reside in the cytoplasmic tail of EGFR. Mutations in these phosphodegron motifs occur in human cancer. CRISPR-mediated disruption of the phosphodegron motif at T693 reduced EGFR degradation and EGF growth factor dependency. FBXW7 mutant organoids showed reduced sensitivity to EGFR-MAPK inhibitors. These observations were further strengthened in CRC-derived organoid lines and validated in a cohort of patients treated with panitumumab. Our data imply that FBXW7 mutations reduce EGF dependency by disabling EGFR turnover.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsF-Box ProteinsHumansF-Box-WD Repeat-Containing Protein 7Ubiquitin-Protein LigasesEpidermal Growth FactorProteomicsErbB Receptors

Stichwörter der Autor:innen

EGFRFBXW7colorectal cancerorganoids

Substanzen

F-Box-WD Repeat-Containing Protein 7Ubiquitin-Protein LigasesEpidermal Growth FactorErbB ReceptorsF-Box ProteinsFBXW7 protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Organoid group, Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, 3584 CT Utrecht, the Netherlands.
  • Department of Molecular and Cellular Biology, Miller Institute for Basic Research in Science, University of California, Berkeley, CA 94720.
  • Singapore Immunology Network, Agency for Science, Technology and Research, Singapore 138648, Singapore.
  • Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore.
  • Department of Biomolecular Mass Spectrometry and Proteomics, Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University,…
  • Department of Medical Oncology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.

ORCID-Profile: Rosemary Millen, Wei Wu, Hans Clevers

Förderung

  • European Molecular Biology Organization (EMBO)

Zitieren

APA

Boretto, M., Geurts, M. H., Gandhi, S., Ma, Z., Staliarova, N., Celotti, M., Lim, S., He, G. W., Millen, R., Driehuis, E., Begthel, H., Smabers, L., Roodhart, J., van Es, J., Wu, W., & Clevers, H. (2024). Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7. Proceedings of the National Academy of Sciences, 121(12). https://doi.org/10.1073/pnas.2309902121

Vancouver

Boretto M, Geurts MH, Gandhi S, Ma Z, Staliarova N, Celotti M, et al. Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7. Proceedings of the National Academy of Sciences. 2024;121(12). doi:10.1073/pnas.2309902121

BibTeX
@article{Boretto2024,
  author = {Boretto, Matteo and Geurts, Maarten H and Gandhi, Shashank and Ma, Ziliang and Staliarova, Nadzeya and Celotti, Martina and Lim, Sangho and He, Gui-Wei and Millen, Rosemary and Driehuis, Else and Begthel, Harry and Smabers, Lidwien and Roodhart, Jeanine and van Es, Johan and Wu, Wei and Clevers, Hans},
  title = {Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  volume = {121},
  number = {12},
  doi = {10.1073/pnas.2309902121}
}
Kostenlos starten →